BridgeBio Pharma Inc

NASDAQ:BBIOUnited States

BridgeBio Pharma, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on discovering, creating, testing and delivering transformative medicines to treat patients who suffer from genetic diseases and cancers with clear genetic drivers. The Company's pipeline of development programs ranges from early science to advanced clinical trials that include Acoramidis (AG10), a next-generation small molecule near-complete transthyretin (TTR) stabilizer, for the treatment of amyloidosis TTR (ATTR); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor (TKI), as a treatment option for children with achondroplasia; Encaleret, a small molecule antagonist of the calcium sensing receptor (CaSR) for the treatment of Autosomal Dominant Hypocalcemia Type 1 (ADH1), and BBP-418, an investigational, orally administered, small molecule substrate supplementation therapy that the Company is developing for the treatment of LGMD2I, also known as LGMDR9.

Contact Information

Headquarters

3160 Porter Dr., Suite 250PALO ALTO, CA, United States 94304

Phone

650-391-9740

Fax

302-655-5049

Executives

President, Chief Executive Officer, Director

Neil Kumar

Chief Financial Officer, Secretary

Brian Stephenson

Lead Director, Chairman of Pharmaceuticals

Charles Homcy

Director

Jennifer Cook

Director

Frank Mccormick